Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trihexyphenidyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 9/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 6/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 5/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 1/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 1.00 |
| ▸ | GRIN2A | Q12879 | 1/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 1/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 1/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Procyclidine SCHEMBL15305878 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Cycrimine SCHEMBL249004 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL34646 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Cycrimine SCHEMBL249005 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL34645 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Procyclidine SCHEMBL147344 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| (S)-Procyclidine SCHEMBL519431 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Procyclidine SCHEMBL121684 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL42410 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 | |
| Trihexyphenidyl SCHEMBL30061697 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6KCNH2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2026-05-07 | — | — | US | claimed |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-11-06 | — | — | US | claimed |
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2025-08-28 | — | — | US | claimed |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | Vima Therapeutics, Inc. (US) | 2025-05-06 | — | — | US | claimed |
| US-20240366583-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2024-11-07 | — | — | US | claimed |
| WO-2024059631-A1 | R-TRIHEXYPHENIDYL FOR TREATMENT OF MOVEMENT DISORDERS | THE CHILDREN’S MERCY HOSPITAL (US) | 2024-03-21 | — | — | WO | claimed |
| US-6207681-B1 | ADMINISTERING ENANTIOMERICALLY ENRICHED (R)-TRIHEXYPHENIDYL ((R)-3-(1-PIPERIDYL)1-CYCLOHEXYL-1-PROPANOL), OR A PHARMACEUTICALLY ACCEPTABLE SALT FOR TREATING URINARY INCONTINENCE | SEPRACOR INC. | 2001-03-27 | — | — | US | claimed |
| US-6063792-A | UROGENITAL DISORDERS | SEPRACOR INC. (US) | 2000-05-16 | — | — | US | claimed |
| EP-0938314-A4 | — | — | 1999-09-01 | — | — | EP | claimed |
| EP-0938314-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (R)-TRIHEXYPHENIDYL | SEPRACOR, INC. (US) | 1999-09-01 | — | — | EP | claimed |
| EP-0923374-A4 | — | — | 1999-07-28 | — | — | EP | claimed |
| EP-0923374-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (S)-TRIHEXYPHENIDYL | SEPRACOR, INC. (US) | 1999-06-23 | — | — | EP | claimed |
| WO-1998000141-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (S)-TRIHEXYPHENIDYL | SEPRACOR, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| WO-1998000140-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (R)-TRIHEXYPHENIDYL | SEPRACOR, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | Vima Therapeutics, Inc. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260083716-A1 | R-TRIHEXYPHENIDYL FOR TREATMENT OF MOVEMENT DISORDERS | THE CHILDREN'S MERCY HOSPITAL (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260083716-A1 | R-TRIHEXYPHENIDYL FOR TREATMENT OF MOVEMENT DISORDERS | THE CHILDREN'S MERCY HOSPITAL (US) | 2026-03-26 | — | — | US | disclosed |
| WO-1998000141-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (S)-TRIHEXYPHENIDYL | SEPRACOR, INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000140-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (R)-TRIHEXYPHENIDYL | SEPRACOR, INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000141-A1 | METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERICALLY ENRICHED (S)-TRIHEXYPHENIDYL | SEPRACOR, INC. (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268883-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM1 8/4885CHRM2 3/4885CYP2D6 1768/4885 |
| US-12290513-B2 | Therapeutic methods and compositions for treating movement disorders | CHRM3, CHRM5, CHRM2 | CHRM1 8/4885CHRM2 3/4885CYP2D6 1768/4885 |
| US-20250339418-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRM5, CHRM2 | CHRM1 8/4885CHRM2 3/4885CYP2D6 1768/4885 |
| US-20260124147-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM5, CHRM4, CHRM2 | CHRM1 11/4885CHRM2 3/4885CYP2D6 1750/4885 |
| US-20240366583-A1 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING MOVEMENT DISORDERS | CHRM3, CHRNA5, CHRNA7 | CHRM1 15/4885CHRM2 7/4885CYP2D6 2368/4885 |
| US-20260083716-A1 | R-TRIHEXYPHENIDYL FOR TREATMENT OF MOVEMENT DISORDERS | CHRM2, CHRM1, CHRM4 | CHRM1 2/4885CHRM2 1/4885CYP2D6 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.